Women's Health 2024: Beyond the Annual Visit - Midwest - October 18, 2024

The quality of healthcare provided to women has never been more relevant. That’s why there’s Women’s Health 2024: Beyond the Annual Visit. Join us!

Live Broadcast
5.00 available credits
Information
October 18, 2024
08:00 AM - 01:30 PM CDT
ReachMD Healthcare Image

This live broadcast will start in exactly:

  • 0

    Day(s)

  • 0

    Hour(s)

  • 0

    Minute(s)

  • 0

    Second(s)

Details
Presenters
Comments
  • Overview

    We're excited to announce Dr. Anita Nelson, Dr. Amy Clouse, and Ms. Barbara Dehn as this year's Planning Committee and Moderators!

    Join the conversation #WH24

    Please see below for when the Live Broadcast will begin in your time zone:

    • 8 AM CT
    • 9 AM ET
    • 7 AM MT
    • 6 AM PT
     
  • Program Schedule

    8:00 – 8:05 AM

    Welcome, Introductions, Program Announcements

    Anita L. Nelson, MD, Barbara Dehn, WHNP-BC, and Amy Clouse, MD

    Program Co-Chairs

      

    8:05 – 8:40 AM

    Breast Cancer Screening and Prevention for Average-Risk Patients

    Anita Nelson, MD

     

     

      

    8:40 – 9:25 AM

    New Hope Emerging in the Treatment of PTSD in Women

    Overcoming Suboptimal Outcomes

    Joseph F. Goldberg, MD & Roger McIntyre, MD

      

    9:25 – 10:00 AM

    How Primary Care Practitioners Can Reduce Maternal Mortality and Morbidity in the US

    Anita Nelson, MD

     

      

    10:00 – 10:15 AM

    Question & Answer Session

      

    10:15 – 10:45 AM

    Break

      

    10:45 – 11:20 AM

    Taking a Sexual History

    Barbara Dehn, WHNP-BC

    11:20 – 11:45 PM            

     

    Importance of Early Diagnosis of Endometriosis: Patient and Clinical Considerations

    Lee Shulman, MD, Linda Bradley, MD, & James A. Simon, MD

    11:45 – 12:35 PM

    Optimizing PPD Diagnosis and Treatment: The Role of Neuroactive Steroids and Multidisciplinary Care

    Kristina M. Deligiannidis, MD & Jennifer L. Payne, MD

     

      

    12:35 – 1:15 PM

    GLP-1 Receptor Agonists: Managing the Hype and the Hope

    Amy Clouse, MD

      

    1:15 – 1:35 PM

    Question & Answer Session & Closing Remarks

     

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Planning Committee:

    Amy Clouse, MD
    Associate Clinical Professor
    Sidney Kimmel Medical College, Thomas Jefferson University
    Associate Residency Director, Family Medicine Residency Program
    Jefferson – Abington Health
    Jenkintown, PA 

    Dr. Clouse has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Astellas

    Barbara Dehn, WHNP-BC
    Nurse Practitioner
    Planned Parenthood
    Albany, NY

    Barbara Dehn has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Acella, Avion, Bonafide, Pharmavite, Shield Therapeutics
    Vendor: Cord Blood Registry

    Anita L. Nelson, MD
    Professor and Chair of Obstetrics & Gynecology
    Western University of Health Sciences, Pomona, CA
    Professor Emeritus, Obstetrics & Gynecology, UCLA
    Los Angeles, CA

    Dr. Nelson has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Bayer, Exeltis USA, Inc, Merck, Myovant, Sumitomo Pharma America, Inc
    Contracted Research: Daré Bioscience,Mylan Pharmaceuticals, Organon & Co, Sebela Pharmaceuticals, Sumitomo Pharma America, Viatris Pharmaceuticals, Inc 

    Faculty:

    Linda Bradley, MD 
    Professor of Obstetrics & Gynecology and
    Reproductive Medicine
    Cleveland Clinic
    Cleveland, OH

    Dr. Bradley has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Receives Royalties: Wolters Kluwer, UpToDate
    Medical Director: AAGL

    Kristina Deligiannidis, MD 
    Director, Women’s Behavioral Health 
    Zucker Hillside Hospital, Northwell Health 
    New York, NY 

    Dr. Deligiannidis has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Premier Healthcare, Sage Therapeutics, Woebot Health 
    Consulting Fees: Biogen, Brii Biosciences, G H Research Ireland, Gerbera Therapeutics, Next Sense, Reunion Neuroscience 

    Joseph F. Goldberg, MD  
    Clinical Professor of Psychiatry  
    Icahn School of Medicine at Mount Sinai  
    New York, NY    

    Dr. Goldberg has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Receives royalties: American Psychiatric Publishing, Cambridge University Press    
    Consulting Fees: Genomind, Intra-Cellular Therapies, Luye Pharmaceuticals, Neumora, Neurelis, Otsuka, Sage Pharmaceuticals, Sunovion, Supernus 
    Speakers' bureau: AbbVie, Alkermes, Axsome, Bristol Myers Squibb 

    Roger McIntyre, MD  
    Professor of Psychiatry and Pharmacology  
    University of Toronto  
    Toronto, Canada    

    Dr. McIntyre has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Research: CIHR/GACD/National Natural Science Foundation of China (NSFC), and the Milken Institute  
    Consulting Fees: Abbvie, Alkermes, atai Life Sciences, Axsome, Bausch Health, Biogen, Boehringer Ingelheim, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris  
    CEO of Braxia Scientific Corp. 

    Jennifer L. Payne, MD
    Professor and Vice Chair of Research
    University of Virginia  
    Charlottesville, VA 

    Dr. Payne has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Janssen, Myriad
    Ownership Interest: Dionysus Health
    Consulting Fees: Biogen, Brii Biosciences, Flo Health, Sage Therapeutics 

    Lee Shulman, MD, FACOG, FACMG 
    The Anna Ross Lapham Professor and Chief
    Division of Clinical Genetics
    Feinberg School of Medicine
    Northwestern University
    Chicago, IL

    Dr. Shulman has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Alliance Pharma, Amazon, Juniper Genomics, Mayne, Shield
    Speaker Fees: Daiichi Sankyo, Mayne, Shield
    Other: Astellas (DSMB Chair)

    James A. Simon, MD, CCD, NCMP, IF, FACOG 
    Clinical Professor, Obstetrics and Gynecology 
    George Washington University 
    Women’s Health & Research Consultants 
    IntimMedicine Specialists 
    Washington, DC 

    Dr. Simon has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Grant/research support: AbbVie, Inc., Bayer Healthcare LLC, Daré Bioscience, Ipsen, Mylan/Viatris Inc., Myovant Sciences, Sebela Pharmaceuticals Inc. 
    Consultant/advisory boards: Ascend Therapeutics, Bayer HealthCare Pharmaceuticals Inc., Besins Healthcare, Biote Medical, LLC, California Institute of Integral Studies (CIIS), Daré Bioscience, Femasys Inc., Khyria, Madorra Pty Ltd., Mayne Pharma, Inc., Pfizer Inc., Vella Bioscience Inc. 
    Speaker's bureaus: Ascend Therapeutics, Astellas Pharma, Inc., Mayne Pharma, Inc., Myovant Sciences, Inc., Pfizer Inc., Pharmavite LLC., Scynexis Inc. 
    Stockholder (direct purchase): Sermonix Pharmaceuticals 

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Brian McDonough has nothing to disclose. 
    • Tim Person has nothing to disclose.
  • Target Audience

    This activity has been designed to meet the educational needs of ob-gyns and ob-gyn advanced practice nurses and physician assistants, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals who manage the health needs of women.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 5.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 5 contact hours/.5 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-103-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by independent educational grant(s) from Otsuka America Pharmaceutical Inc. and Sage Therapeutics, Inc. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Details
Presenters
Comments
  • Overview

    We're excited to announce Dr. Anita Nelson, Dr. Amy Clouse, and Ms. Barbara Dehn as this year's Planning Committee and Moderators!

    Join the conversation #WH24

    Please see below for when the Live Broadcast will begin in your time zone:

    • 8 AM CT
    • 9 AM ET
    • 7 AM MT
    • 6 AM PT
     
  • Program Schedule

    8:00 – 8:05 AM

    Welcome, Introductions, Program Announcements

    Anita L. Nelson, MD, Barbara Dehn, WHNP-BC, and Amy Clouse, MD

    Program Co-Chairs

      

    8:05 – 8:40 AM

    Breast Cancer Screening and Prevention for Average-Risk Patients

    Anita Nelson, MD

     

     

      

    8:40 – 9:25 AM

    New Hope Emerging in the Treatment of PTSD in Women

    Overcoming Suboptimal Outcomes

    Joseph F. Goldberg, MD & Roger McIntyre, MD

      

    9:25 – 10:00 AM

    How Primary Care Practitioners Can Reduce Maternal Mortality and Morbidity in the US

    Anita Nelson, MD

     

      

    10:00 – 10:15 AM

    Question & Answer Session

      

    10:15 – 10:45 AM

    Break

      

    10:45 – 11:20 AM

    Taking a Sexual History

    Barbara Dehn, WHNP-BC

    11:20 – 11:45 PM            

     

    Importance of Early Diagnosis of Endometriosis: Patient and Clinical Considerations

    Lee Shulman, MD, Linda Bradley, MD, & James A. Simon, MD

    11:45 – 12:35 PM

    Optimizing PPD Diagnosis and Treatment: The Role of Neuroactive Steroids and Multidisciplinary Care

    Kristina M. Deligiannidis, MD & Jennifer L. Payne, MD

     

      

    12:35 – 1:15 PM

    GLP-1 Receptor Agonists: Managing the Hype and the Hope

    Amy Clouse, MD

      

    1:15 – 1:35 PM

    Question & Answer Session & Closing Remarks

     

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Planning Committee:

    Amy Clouse, MD
    Associate Clinical Professor
    Sidney Kimmel Medical College, Thomas Jefferson University
    Associate Residency Director, Family Medicine Residency Program
    Jefferson – Abington Health
    Jenkintown, PA 

    Dr. Clouse has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Astellas

    Barbara Dehn, WHNP-BC
    Nurse Practitioner
    Planned Parenthood
    Albany, NY

    Barbara Dehn has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Acella, Avion, Bonafide, Pharmavite, Shield Therapeutics
    Vendor: Cord Blood Registry

    Anita L. Nelson, MD
    Professor and Chair of Obstetrics & Gynecology
    Western University of Health Sciences, Pomona, CA
    Professor Emeritus, Obstetrics & Gynecology, UCLA
    Los Angeles, CA

    Dr. Nelson has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Bayer, Exeltis USA, Inc, Merck, Myovant, Sumitomo Pharma America, Inc
    Contracted Research: Daré Bioscience,Mylan Pharmaceuticals, Organon & Co, Sebela Pharmaceuticals, Sumitomo Pharma America, Viatris Pharmaceuticals, Inc 

    Faculty:

    Linda Bradley, MD 
    Professor of Obstetrics & Gynecology and
    Reproductive Medicine
    Cleveland Clinic
    Cleveland, OH

    Dr. Bradley has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Receives Royalties: Wolters Kluwer, UpToDate
    Medical Director: AAGL

    Kristina Deligiannidis, MD 
    Director, Women’s Behavioral Health 
    Zucker Hillside Hospital, Northwell Health 
    New York, NY 

    Dr. Deligiannidis has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Premier Healthcare, Sage Therapeutics, Woebot Health 
    Consulting Fees: Biogen, Brii Biosciences, G H Research Ireland, Gerbera Therapeutics, Next Sense, Reunion Neuroscience 

    Joseph F. Goldberg, MD  
    Clinical Professor of Psychiatry  
    Icahn School of Medicine at Mount Sinai  
    New York, NY    

    Dr. Goldberg has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Receives royalties: American Psychiatric Publishing, Cambridge University Press    
    Consulting Fees: Genomind, Intra-Cellular Therapies, Luye Pharmaceuticals, Neumora, Neurelis, Otsuka, Sage Pharmaceuticals, Sunovion, Supernus 
    Speakers' bureau: AbbVie, Alkermes, Axsome, Bristol Myers Squibb 

    Roger McIntyre, MD  
    Professor of Psychiatry and Pharmacology  
    University of Toronto  
    Toronto, Canada    

    Dr. McIntyre has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Research: CIHR/GACD/National Natural Science Foundation of China (NSFC), and the Milken Institute  
    Consulting Fees: Abbvie, Alkermes, atai Life Sciences, Axsome, Bausch Health, Biogen, Boehringer Ingelheim, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris  
    CEO of Braxia Scientific Corp. 

    Jennifer L. Payne, MD
    Professor and Vice Chair of Research
    University of Virginia  
    Charlottesville, VA 

    Dr. Payne has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Janssen, Myriad
    Ownership Interest: Dionysus Health
    Consulting Fees: Biogen, Brii Biosciences, Flo Health, Sage Therapeutics 

    Lee Shulman, MD, FACOG, FACMG 
    The Anna Ross Lapham Professor and Chief
    Division of Clinical Genetics
    Feinberg School of Medicine
    Northwestern University
    Chicago, IL

    Dr. Shulman has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Alliance Pharma, Amazon, Juniper Genomics, Mayne, Shield
    Speaker Fees: Daiichi Sankyo, Mayne, Shield
    Other: Astellas (DSMB Chair)

    James A. Simon, MD, CCD, NCMP, IF, FACOG 
    Clinical Professor, Obstetrics and Gynecology 
    George Washington University 
    Women’s Health & Research Consultants 
    IntimMedicine Specialists 
    Washington, DC 

    Dr. Simon has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Grant/research support: AbbVie, Inc., Bayer Healthcare LLC, Daré Bioscience, Ipsen, Mylan/Viatris Inc., Myovant Sciences, Sebela Pharmaceuticals Inc. 
    Consultant/advisory boards: Ascend Therapeutics, Bayer HealthCare Pharmaceuticals Inc., Besins Healthcare, Biote Medical, LLC, California Institute of Integral Studies (CIIS), Daré Bioscience, Femasys Inc., Khyria, Madorra Pty Ltd., Mayne Pharma, Inc., Pfizer Inc., Vella Bioscience Inc. 
    Speaker's bureaus: Ascend Therapeutics, Astellas Pharma, Inc., Mayne Pharma, Inc., Myovant Sciences, Inc., Pfizer Inc., Pharmavite LLC., Scynexis Inc. 
    Stockholder (direct purchase): Sermonix Pharmaceuticals 

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Brian McDonough has nothing to disclose. 
    • Tim Person has nothing to disclose.
  • Target Audience

    This activity has been designed to meet the educational needs of ob-gyns and ob-gyn advanced practice nurses and physician assistants, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals who manage the health needs of women.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 5.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 5 contact hours/.5 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-103-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by independent educational grant(s) from Otsuka America Pharmaceutical Inc. and Sage Therapeutics, Inc. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Register

We're glad to see you're enjoying Omnia Education…
but how about a more personalized experience?

Register for free